Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 long-term extension study of litifilimab in adults with active systemic lupus erythematosus
NL-OMON51320Phase 3Not yet recruiting
- Sponsor
- Biogen
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of litifilimab in systemic lupus erythematosus (SLE) (2 arms), sponsored by Biogen. Primary endpoints: Incidence of treatment-emergent adverse events and Incidence of serious adverse events. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
litifilimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON51320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51320.